IDH2 and central nervous system cancer: As a use-case, we consider the development of a predictive model to determine the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutation status from basic structural standard-of-care medical images5 and genomic data from TCIA/TCGA low-grade gliomas (LGG) and glioblastomas multiform (GBM) public archives.